Rapt Therapeutics Inc (NASDAQ:RAPT)
| 19.39 Delayed Data As of Mar 20 |  +0.48 / +2.53%Today’s Change | 9.86 Today|||52-Week Range 32.45 | -2.07% Year-to-Date |
Latest RAPT News | Press Releases
| Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates Mar 08 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 18.94 |
| Today’s open | 19.14 |
| Day’s range | 18.68 - 19.49 |
| Volume | 304,213 |
| Average volume (3 months) | 469,134 |
| Market cap | $649.1M |
Data as of 4:00pm ET, 03/20/2023
Growth & Valuation
| Earnings growth (last year) | -15.29% |
| Earnings growth (this year) | -1.17% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -24.38% |
| P/E ratio | NM |
| Price/Sales | 263.85 |
| Price/Book | 3.06 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BCYCBicycle Therapeutics... | -0.42 | -1.93% |
| ADMAADMA Biologics Inc | -0.02 | -0.65% |
| IBRXImmunitybio Inc | -0.06 | -4.26% |
| ---- |
Data as of 3:59pm ET, 03/20/2023
Financials
| Next reporting date | May 10, 2023 |
| EPS forecast (this quarter) | -$0.67 |
| Annual revenue (last year) | $3.8M |
| Annual profit (last year) | -$69.2M |
| Net profit margin | -1,814.95% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
